Category: Osteoporosis

In osteoporosis care, Prolia® (denosumab) has become a mainstay therapy for patients at high risk of fracture. By targeting the RANKL pathway, Prolia reduces osteoclast formation and activity, slowing bone resorption and improving bone mineral density (BMD). For healthcare providers, mastering its mechanism, safety profile, and patient selection criteria is key to optimizing outcomes and …

Prolia for Osteoporosis: A Comprehensive Guide for Healthcare ProvidersRead More